SR One

Activity from announced rounds

All recorded activity
Rounds participated in
7
Confirmed lead rounds
0
5 roles undisclosed
New companies
6
First participation on record · 1 follow-on
Funding in participating rounds
$840M
6 disclosed · full round size, not this investor’s share

By stage

Series A3
Series B2
Series C+1
Undisclosed1

By primary sector

Biotech6
Healthtech1

By country

United States5
China1
United Kingdom1

Rounds

7 in all activity
Dren Bio

Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.

$350MPrivate financing
Participant
Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B
Role not disclosed
Poplar Therapeutics

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$45MSeries A+
Role not disclosed
Corxel Pharmaceuticals

Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.

≤$287MSeries D1
Participant
AirNexis Therapeutics

AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.

$200MSeries A
Role not disclosed
Poplar Therapeutics

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$50MSeries A
Role not disclosed